For Pet's Sake: Understanding feline hypertrophic cardiomyopathy (HCM)
Feline Hypertrophic Cardiomyopathy (HCM) is the most common heart disease in cats, affecting felines of all breeds and ...
Yahoo Finance4d
Four New Studies Demonstrate that Viz.ai Finds New Patients with Hypertrophic Cardiomyopathy Earlier When Embedded into the Clinical Workflow
Real-world evidence to be presented at the American College of Cardiology Scientific Session 2025 demonstrates positive impact of Viz.ai on disease detection and care coordination SAN FRANCISCO ...
Modern Ghana12d
Beyond Medication: Integrative Therapies for Hypertrophic Cardiomyopathy
Imagine receiving a diagnosis that changes your life in an instant: hypertrophic cardiomyopathy, a heart condition that can strike without warning, claiming thousands of lives annually .
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to CareSOUTH SAN FRANCISCO, Calif., ...
Nasdaq10d
Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care
an interactive online tool aimed at improving awareness and understanding of hypertrophic cardiomyopathy (HCM) in the U.S. Developed with input from prominent academic institutions, the tool ...
WGN Radio 7204h
Major advancements and breakthroughs for your cat’s health; How your dog can become an assisted therapy animal; and more
Pretty much everything we know about cats was once funded by the non-profit – EveryCat Health Foundation. Jackie Ott Jaakola, Executive Director, explains further and how recently treatments ...
Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25
Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heartfailure-related health status (KCCQ) in ...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201SOUTH ...
American Association of Individual Investors4d
Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 10.14%
Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 10.14%, which has investors questioning if this is right time to ...
Morningstar4d
Four New Studies Demonstrate that Viz.ai Finds New Patients with Hypertrophic Cardiomyopathy Earlier When Embedded into the Clinical Workflow
“It’s exciting to see the growing real-world evidence showing how AI-enhanced ECG analysis can play a pivotal role in identifying new patients with hypertrophic cardiomyopathy,” said Milind ...